BMY — Bristol-Myers Squibb Company
$61.61+0.21%
Last close: · regular session
Last 60 sessions
BMY closed at $61.61 (+0.21%) on Oct 26, 2026. Float: 2.0B shares. Latest SEC filing: 10-Q on Jul 30, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for BMY in the TickerWise workspace.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NYSE
- Employees: 34,100
- Website: https://www.bms.com
Latest SEC filings for BMY
Latest BMY news
- Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings? Read article
- Bristol Myers Squibb (BMY) Sees a More Significant Dip Than Broader Market: Some Facts to Know Read article
- BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? Read article
- Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio? Read article
- Bristol-Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? Read article
- Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It Read article
- BMY Reports Mixed Phase III Trial Results, Stock Down Read article
- Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.